Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry

JACC: Cardiovascular Interventions

Volumn 11, Issue 17, 2018, Pages 1746-1756

  Vora, Amit N ^a,b   Dai, Dadi ^b   Matsuoka, Roland ^b   Harrison, J Kevin ^a   Hughes, G Chad ^a   Sherwood, Matthew W ^c   Piccini, Jonathan P ^a,b   Bhardwaj, Bhaskar ^d   Lopes, Renato D ^a   Cohen, David ^e   Holmes, David R ^f   Thourani, Vinod H ^g   Peterson, Eric ^a,b   Kirtane, Ajay ^h   Kapadia, Samir ⁱ   Vemulapalli, Sreekanth ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c INOVA HEART AND VASCULAR INSTITUTE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atrial fibrillation; TAVR

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

AGE; AGED; ALL CAUSE MORTALITY; ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHA2DS2-VASC SCORE; CHRONIC LUNG DISEASE; CLINICAL OUTCOME; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HOSPITAL MORTALITY; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEW-ONSET ATRIAL FIBRILLATION; PRIORITY JOURNAL; RISK FACTOR; TRANSCATHETER AORTIC VALVE IMPLANTATION; VASCULAR ACCESS; ADVERSE EVENT; ATRIAL FIBRILLATION; MORTALITY; REGISTER; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 85052215409     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2018.05.042     Document Type: Article

References (31)

1. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
2. Maan, A., Heist, E.K., Passeri, J., et al. Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol 115 (2015), 220–226.
3. Tanawuttiwat, T., O'Neill, B.P., Cohen, M.G., et al. New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. J Am Coll Cardiol 63 (2014), 1510–1519.
4. Holmes, D.R. Jr., Brennan, J.M., Rumsfeld, J.S., et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 313 (2015), 1019–1028.
5. Adams, D.H., Popma, J.J., Reardon, M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
6. Leon, M.B., Smith, C.R., Mack, M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
7. Popma, J.J., Adams, D.H., Reardon, M.J., et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63 (2014), 1972–1981.
8. Smith, C.R., Leon, M.B., Mack, M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
9. Tarantini, G., Mojoli, M., Urena, M., Vahanian, A., Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J 38 (2017), 1285–1293.
10. Tarantini, G., Mojoli, M., Windecker, S., et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. J Am Coll Cardiol Intv 9 (2016), 937–946.
11. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
12. Mack, M.J., Brennan, J.M., Brindis, R., et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 310 (2013), 2069–2077.
13. Carroll, J.D., Edwards, F.H., Marinac-Dabic, D., et al. The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies. J Am Coll Cardiol 62 (2013), 1026–1034.
14. Holmes, D.R. Jr., Nishimura, R.A., Grover, F.L., et al. Annual outcomes with transcatheter valve therapy: from the STS/ACC TVT Registry. J Am Coll Cardiol 66 (2015), 2813–2823.
15. Fang, M.C., Go, A.S., Chang, Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 58 (2011), 395–401.
16. Edwards, F.H., Cohen, D.J., O'Brien, S.M., et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiology 1 (2016), 46–52.
17. Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
18. Erdoes, G., Lippuner, C., Kocsis, I., et al. Technical approach determines inflammatory response after surgical and transcatheter aortic valve replacement. PLoS ONE, 10, 2015, e0143089.
19. Stahli, B.E., Grunenfelder, J., Jacobs, S., et al. Assessment of inflammatory response to transfemoral transcatheter aortic valve implantation compared to transapical and surgical procedures: a pilot study. J Invasive Cardiol 24 (2012), 407–411.
20. Prakash, A., Delfaut, P., Krol, R.B., Saksena, S., Regional right and left atrial activation patterns during single- and dual-site atrial pacing in patients with atrial fibrillation. Am J Cardiol 82 (1998), 1197–1204.
21. Sparks, P.B., Mond, H.G., Vohra, J.K., Jayaprakash, S., Kalman, J.M., Electrical remodeling of the atria following loss of atrioventricular synchrony: a long-term study in humans. Circulation 100 (1999), 1894–1900.
22. Sparks, P.B., Mond, H.G., Vohra, J.K., Yapanis, A.G., Grigg, L.E., Kalman, J.M., Mechanical remodeling of the left atrium after loss of atrioventricular synchrony. A long-term study in humans. Circulation 100 (1999), 1714–1721.
23. Waktare, J.E., Hnatkova, K., Sopher, S.M., et al. The role of atrial ectopics in initiating paroxysmal atrial fibrillation. Eur Heart J 22 (2001), 333–339.
24. Gillinov, A.M., Bagiella, E., Moskowitz, A.J., et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 374 (2016), 1911–1921.
25. Rodes-Cabau, J., Masson, J.B., Welsh, R.C., et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. J Am Coll Cardiol Intv 10 (2017), 1357–1365.
26. Urena, M., Hayek, S., Cheema, A.N., et al. Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation 131 (2015), 469–477.
27. Nombela-Franco, L., Webb, J.G., de Jaegere, P.P., et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 126 (2012), 3041–3053.
28. Kapadia, S.R., Krishnaswamy, A., Tuzcu, E.M., Atrial fibrillation and transcatheter aortic valve replacement: implications of pre-procedural identification of left atrial appendage thrombus for stroke prevention. J Am Coll Cardiol Intv 10 (2017), 185–187.
29. Windecker, S., Tijssen, J., Giustino, G., et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J 184 (2017), 81–87.
30. Nijenhuis, V.J., Bennaghmouch, N., Hassell, M., et al. Rationale and design of POPular-TAVI: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation. Am Heart J 173 (2016), 77–85.
31. Brennan, J.M., O'Brien, S., Milford-Beland, S., et al. Abstract 26: comparison of Medicare claims with clinical trial outcomes for follow-up of older individuals with acute coronary syndrome. Circ Cardiovasc Qual Outcomes, 7, 2014, A26.